Getting under the skin of people with type 1 diabetes – but in a good way

THIS BLOG IS ALSO AVAILABLE AS AN AUDIOCAST As someone with a family history of type 1 diabetes (T1D) I know how devastating the condition can be. I also know how challenging it can be to keep it under control and the consequences of failing to do that. Not maintaining healthy blood sugar levels can … Continue reading Getting under the skin of people with type 1 diabetes – but in a good way

First Patient Dosed in Phase 1 Clinical Trial for T1D

THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST There’s some good news for a company and a therapeutic approach that CIRM has been supporting for many years. In September 2018, CRISPR Theraputics and ViaCyte entered a partnership to discover, develop and market gene-edited stem cell-derived therapies to treat type 1 diabetes (T1D). Today, they may stand … Continue reading First Patient Dosed in Phase 1 Clinical Trial for T1D

Scientists develop immune evading pancreas organoids to treat type 1 diabetes

By Stephen Lin, PhD., CIRM Senior Science Officer Type 1 diabetes affects millions of people.  It is a disease where beta islet cells in the pancreas are targeted by the body’s own immune system, destroying the ability to produce insulin.  Without insulin, the body cannot break down sugars from the bloodstream that produce energy for … Continue reading Scientists develop immune evading pancreas organoids to treat type 1 diabetes

The Most Read Stem Cellar Blog Posts of 2021

THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST This year was a momentous one for the California Institute for Regenerative Medicine (CIRM). We celebrated the passage of Proposition 14, and as a result, introduced our new strategic plan and added a group of talented individuals to our team.   We shared our most exciting updates and newsworthy stories—topics ranging from stem cell research to diversity … Continue reading The Most Read Stem Cellar Blog Posts of 2021